Ribociclib-d8
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Ribociclib-d8
Description:
Ribociclib-d8 is the deuterium labeled Ribociclib[1]. Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[2].Product Name Alternative:
LEE011-d8UNSPSC:
12352005Hazard Statement:
H301, H315, H319, H372, H400Target:
CDKType:
Isotope-Labeled CompoundsRelated Pathways:
Cell Cycle/DNA DamageApplications:
Cancer-Kinase/proteaseField of Research:
CancerPurity:
99.23Solubility:
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)Smiles:
CN(C)C(C(N(C1CCCC1)C2=N3)=CC2=CN=C3NC4=CC=C(N5C([2H])([2H])C([2H])([2H])NC([2H])([2H])C5([2H])[2H])C=N4)=OMolecular Formula:
C23H22D8N8OMolecular Weight:
442.59Precautions:
H301, H315, H319, H372, H400References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res. 2015 Jul 1;21 (13) :2905-10.|[3]Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 1519 (22) :6173-82.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Isotope-Labeled CompoundsClinical Information:
No Development ReportedCAS Number:
[2167898-24-8]
